Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Yissum and Hadasit license regenerative polymeric membrane implants to RegeneCure
Pre-clinical trial shows excellent healing and complete bone repair 8 weeks post–osteotomy


March 7, 2011

JERUSALEM - Yissum Research Development Company Ltd., the technology transfer company of the Hebrew University of Jerusalem, and Hadasit Medical Research Services & Development Ltd., the technology transfer company of the Hadassah University Medical Center, today announced that they have licensed innovative regenerative membrane implant technology to RegeneCure, which will further develop and commercialize the technology for bone tissue engineering for applications in trauma, spine, and reconstructive cranial and facial orthopedics. The technology was invented by Professor Michael Friedman from the Institute of Drug Research at the Hebrew University of Jerusalem and Prof. Rami Mosheiff. M.D., Head of Orthopedic Trauma Center, Hadassah Medical Center, Jerusalem.

Under the terms of the agreement, RegeneCure has received the worldwide exclusive right to develop and commercialize the technology. In return, Yissum and Hadasit will receive license fees, milestones and royalty payments from future sales of the final product.

The membrane implant has a microporous surface that facilitates adherence of bone stem cells (MSCs) recruited to the injured site through a signaling mechanism known as chemotaxis. The membrane optimizes proliferation and differentiation of the MSCs into bone tissue in the area of need. In addition, the membrane implant serves as an effective barrier that does not allow scar tissue to infiltrate into the fracture and slow down the regenerative healing process. Current methods that facilitate bone regeneration and healing of non-union fractures are based on autografts, bone transplantation from the patient's body, or else by adding bone graft substitutes that help fill the fractured gap. In contrast, RegeneCure’s MSC scaffolding method improves natural bone healing due to the ability of the tubular implant to attract bone stem cells, enhance their proliferation and rapidly form new bone tissue.

RegeneCure has successfully completed a preclinical study to determine the safety and efficacy of the implant in animal models that mimic bone loss that creates a gap in the bone as result of trauma or disease and cannot be repaired spontaneously. The study, which took place in Hadassah Medical Center in Jerusalem, compared between 3 groups: animals implanted with RegeneCure's implant, those implanted with an alternative implant and untreated animals. Eight weeks post implantation, results clearly demonstrate that the healing process of animals implanted with RegeneCure's implant is far better than the alternative implant in all healing parameters. Healing rate measured by quantity of new bone formed was higher and the bone gap was completely bridged and integrated in 100% of the cases.

The membrane implant is recognized as a medical device, enabling an expedited regulatory pathway. Pre-clinical studies in larger animals are expected to begin in May 2011, and results are expected in October 2011. This will be followed by FDA and CE submissions towards the end of 2011.

'This biocompatible and user friendly membrane implant is suited for a large range of acute and chronic spine and craniofacial conditions that are characterized by delayed or lack of bone healing due to bone deficit. The innovative membrane implant was shown to be safe and effective, resulting in a high rate of bone healing in critical size defect animal trials. Since the bone physiology of the studied animal model is highly similar to that of humans, we believe that RegeneCure's implant has an excellent potential to substitute the bone grafting treatment that is currently considered the gold standard. Our technology can thus eliminate the additional surgical procedures that are required in current treatments,' said Moshe Tzabari, CEO of RegeneCure.

About Yissum

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. was founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies in the world, Yissum has registered over 7,000 patents covering 2,023 inventions; has licensed out 530 technologies and has spun-off 72 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales. Yissum’s business partners span the globe and include companies such as Syngenta, Vilmorin, Monsanto, Novartis, Johnson & Johnson, Roche, Merck, Teva, Google, Adobe, Phillips and many more. For further information please visit www.yissum.co.il.

About Hadasit

Hadasit Medical Research Services & Development Ltd. (www.hadasit.co.il), the technology transfer company of Hadassah Medical Organization (HMO) in Jerusalem, Israel, was established in 1986. Hadasit promotes and commercializes HMO’s continuously generated intellectual property (IP) and R&D capabilities. IP generated by HMO has already gained global recognition due to Hadasit’s successful enterprising of Hadassah’s biomedical technology, including novel therapeutics, diagnostics and devices. Out of more than 30 companies established by Hadasit, seven are currently operating under Hadasit Bio-Holdings (TASE: HDST), its publicly-traded subsidiary.

About RegeneCure

RegeneCure develops regenerative and user-friendly implants that help the body heal faster, with minimal invasive procedures. In 2010, RegeneCure established its state-of-the-art development and manufacturing facilities in Jerusalem. The company brings together a team with vast experience in drug development and entrepreneurs in the field of polymer technology for medical devices. Further information is available at www.regenecure.co.il.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6636726&lang=en


Contacts

Yissum Ltd.
Tsipi Haitovsky, Media Liaison
+972-52-598-9892
tsipih@yissum.co.il
or
Hadasit Medical Research Services & Development Ltd.
Einat Zisman, Ph.D., CEO
+972-2-6778757
einat.zisman@hadassah.org.il


Publisher Contact Information:

Hadasit Medical Research Services & Development Ltd.
+972-2-6778757
einat.zisman@hadassah.org.il

Company profile of Yissum Research Development Company
Past press releases of Yissum Research Development Company.

Data


19,103
Tech investments
From our Online Data Service
12,287
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 17€1.0MMedical devices
Nov 17€3.2MeLearning
Nov 17€3.5MWireless applications
Nov 14€0.3MInternet commerce
Nov 14€2.0MAudio/Video
Nov 14N/AInternet commerce
Nov 13N/AInternet commerce

For information on Europe's most extensive database on technology funding click here!

Events


LeWeb'14 Paris
December 9 - 11, 2014


Press Releases


Nov 24
Curetis
curetis closes eur 14.5 million extension of series b financing

Nov 21
High-Tech Gründerfonds Management
new safety-solution for industrial applications: keeper – beeper – ...

Nov 21
Magic Event
magicevent.com raises 1 million euros for their accommodation websi...

Nov 20
Autifony Therapeutics
autifony announces initiation of phase iia study for first-in-class...

Nov 19
Aquamarine Power
wavepod prototype produces first power





About usContact usLegal Information
Copyright © 1999-2014
Emerging Technology Research Europe Inc. All rights reserved.